TG Therapeutics, Inc. Revenue 2011–2025
TG Therapeutics, Inc. reported $616.29M of revenue for fiscal 2025. That was 87.3% higher than fiscal 2024. Compared with fiscal 2020, the change was +405352.0%.
| Fiscal year | Revenue | Change (YoY) |
|---|---|---|
| FY 2025 | $616.29M | +87.3% |
| FY 2024 | $329.00M | +40.8% |
| FY 2023 | $233.66M | +8290.0% |
| FY 2022 | $2.79M | -58.4% |
| FY 2021 | $6.69M | +4300.7% |
| FY 2020 | $152,000 | +0.0% |
| FY 2019 | $152,000 | +0.0% |
| FY 2018 | $152,000 | +0.0% |
| FY 2017 | $152,000 | +0.0% |
| FY 2016 | $152,000 | — |
| FY 2015 | $0 | — |
| FY 2014 | $0 | — |
| FY 2013 | $0 | — |
| FY 2012 | $0 | — |
| FY 2011 | $0 | — |
Source: TG Therapeutics, Inc. SEC filings — income statement (10-K). Computed deterministically; refreshed nightly (last updated August 2, 2026). Open TGTX 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
TG Therapeutics, Inc. reported $616.29M of revenue for fiscal 2025. That was 87.3% higher than fiscal 2024. Compared with fiscal 2020, the change was +405352.0%. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for TG Therapeutics, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeTG Therapeutics, Inc. — frequently asked questions
What is TG Therapeutics, Inc.'s revenue?
TG Therapeutics, Inc. (TGTX) reported revenue of $616.29M for fiscal year 2025, per its SEC filings.
Where does this data come from?
Figures are computed from TG Therapeutics, Inc.'s official SEC filings (income statement (10-K)), refreshed nightly. Not investment advice.